• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Study Looks at Use of TMS to Treat Depression

Study Looks at Use of TMS to Treat Depression

September 1, 2012
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Subject:
Depression

Short Description:
Study Looks at Use of TMS to Treat Depression

Background:

Transcranial magnetic stimulation, or TMS, was approved by the FDA for treatment of major depression in October 2008. A newly published observational study evaluating the effectiveness of TMS treatment in more than 300 patients at 42 clinical settings across the United States has found that most patients responded well to this intervention, with few adverse effects (Carpenter LL et al, Dep Anx 2012;29(8):587–596).

The study followed 307 outpatients who were approved for TMS treatment due to failing at least one antidepressant trial (multiple failures were not required). Most treatment settings (76%) were private clinical practices, and TMS was paid for either by patients themselves or by their insurance provider. Importantly, both subjects and investigators received a “modest remuneration” for their participation in the study. Also, there was no control or “sham TMS” group.

The primary outcome measure was the Clinical Global Impressions-Severity of Illness (CGI-S) scale. This scale simply asks the question “how mentally ill is the patient at this time,” measured by the clinician on a scale of 0 to 7. In the study, mean CGI-S scores decreased from 5.1 at the start of treatment to 3.2 at the end of treatment (ie, the point at which the clinician felt “maximum improvement” was reached). Response rate was 58.0% while remission rate was 37.1%. Similar results were found on two secondary outcome measures, the patient self-rating scales PHQ-9 and IDS.

Given the generally positive results, investigators searched for patient-specific factors that might predict a beneficial response to TMS. They found that patients younger than 55 years of age and who had less severe depression were more likely to benefit from treatment than others. Furthermore, those who had failed only one antidepressant (54% of the sample) did better than those who had failed two or more.

TCPR's Take:
At first glance, this naturalistic study seems to show an impressive benefit of TMS in real-world settings. Side effects were minimal (there was one seizure, in a woman taking several concurrent medications who was “sleep-deprived” at the time of TMS) even with an average of 28.3 TMS sessions over 42 days. However, the take-home message is called into question by the absence of a control group, the financial incentive to both patients and providers, and the sponsorship of the paper by the TMS device manufacturer. Most important, given the increasing emphasis on placebo response and patient expectations, it would have been interesting to determine whether patients’ (or providers’) beliefs about TMS influenced response to treatment, but this was not assessed.
General Psychiatry
KEYWORDS depressive_disorder research_updates
    Ccpr octnovdec2020 qa1 headshot spielmans 150x150
    Glen Spielmans, PhD

    L-Methylfolate May Offer Modest Boost to Antidepressants

    More from this author
    www.thecarlatreport.com
    Issue Date: September 1, 2012
    SUBSCRIBE NOW
    Table Of Contents
    Helping Patients with Eating Disorders
    Study Looks at Use of TMS to Treat Depression
    Parasite Infection Possible Precursor to Suicidal Behavior
    Study Suggests DCS Not Effective in PTSD Treatment
    Eating Disorder Treatment Challenges
    Eating Disorder Treatment Resources
    Eating Disorders as Addictions
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.